- ►annals.org W Khovidhunkit, DM Shoback - Annals of internal medicine, 1999 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Purpose: To review clinical data on raloxifene hydrochloride, a selective ... Cited by 143 - Related articles - BL Direct - All 6 versions
В Ховидункит, ДМ Шобак - mediasphera.ru Проанализировать клинические данные об
использовании ралоксифена — селективного
модулятора эстрогеновых рецепторов (ЭР), ... Related articles - All 2 versions
A Saitta, N Morabito, N Frisina, DCF Corrado, … - Cardiovascular drug reviews, 2001 - interscience.wiley.com Raloxifene hydrochloride binds to the estrogen receptor and shows
tissue-selective effects; thus, it belongs to a class of drugs recently
described as selective estrogen receptor modulators (SERMs). Tissue ... Cited by 23 - Related articles - BL Direct - All 5 versions
MJ Kayath - Arquivos Brasileiros de Endocrinologia & Metabologia, 1999 - SciELO Brasil Raloxifeno é um modulador seletivo do receptor de estrógeno de segun- da
geração com ação agonista no osso e sistema cardiovasculare ação
antagonista na mama e útero. Sua seletividade tecidual ocorredevido a ... Related articles - View as HTML - All 3 versions
EG LUFKIN, MD WHITAKER, T NICKELSEN, … - Journal of Bone and Mineral Research, 1998 - Am Soc Bone Min Res Raloxifene is a selective estrogen receptor modulator that in experimental
animals acts as an estrogen receptor antagonist in breast and endometrium but as
an estrogen receptor agonist in the skeletal and cardiovascular systems. We ... Cited by 199 - Related articles - BL Direct - All 7 versions
SR Goldstein, WH Scheele, SK Rajagopalan, … - Obstetrics & Gynecology, 2000 - journals.lww.com Department of Obstetrics and Gynecology, New York University School of Medicine,
New York, New York; Lilly Research Laboratories, Eli Lilly and Company,
Indianapolis, Indiana; the Department of Obstetrics and Gynecology, Brigham ... Cited by 121 - Related articles - BL Direct - All 5 versions
KR Snyder, N Sparano, JM Malinowski - American Journal of Health-System Pharmacy, 2000 - ASHP K ELLY R. S NYDER , P HARM .D., BCPS, is Assistant Professor, Pharmacy Practice,
Wilkes University (WU), Wilkes-Barre, PA, and Clinical Special- ist, Family
Medicine, Geisinger Health System, Wilkes-Barre. N Cited by 71 - Related articles - BL Direct - All 8 versions
- ►ama-assn.org [PDF] BW Walsh, LH Kuller, RA Wild, S Paul, M … - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context.— Raloxifene ... Cited by 654 - Related articles - BL Direct - All 6 versions
SM Boss, WJ Huster, JA Neild, MD Glant, CC … - American journal of obstetrics and gynecology, 1997 - Elsevier On the basis of these preclinical studies, no stimulatory effects of raloxifene
were anticipated in the endometrium of postmenopausal women. However, no scoring
system had been devised that allowed classification of the full spectrum of ... Cited by 135 - Related articles - BL Direct - All 4 versions
JA Balfour, KL Goa - Drugs & aging, 1998 - ncbi.nlm.nih.gov Raloxifene is a selective estrogen receptor modulator which mimics the effects
of estrogens on bone and blood lipid levels without stimulatory effects on the
breast or uterus. Raloxifene inhibits estrogen-dependent proliferation of ... Cited by 62 - Related articles - BL Direct - All 2 versions
